{
}
The Goldman Sachs Group reported a strong quarterly performance with earnings per share of $11.95, exceeding estimates, and a revenue of $13.87 billion, up 22.5% year-over-year. Despite a Hold rating from analysts, several firms have adjusted their price targets, with an average target of $590.60. The company also announced a quarterly dividend of $3.00, yielding 2.21%.
Summit Securities Group LLC acquired a new stake in The Goldman Sachs Group, purchasing 14,600 shares valued at approximately $8.36 million, making it the firm's 7th largest position. Insider trading saw significant sales, with Kathryn H. Ruemmler selling 7,498 shares for nearly $4.76 million. The company reported strong quarterly earnings, beating estimates with $11.95 EPS and a revenue of $13.87 billion, reflecting a 22.5% year-over-year increase.
Goldman Sachs has raised its price target for AstraZeneca shares to £151.30, maintaining a Conviction Buy rating, citing an 18% revenue growth and potential in the oral PCSK9 inhibitor market with AZD0780. The anticipated Phase 2 PURSUIT trial data, due on March 31, 2025, is expected to significantly impact the competitive landscape. AstraZeneca is also investing $2.5 billion in a new R&D center in Beijing, enhancing its presence in China and focusing on early-stage research and clinical development.
The High Potency Active Pharmaceutical Ingredients Market is experiencing significant growth, driven by increased demand, technological advancements, and a broadening customer base. A comprehensive report provides insights into market trends, competitive landscape, and future opportunities, highlighting key players such as Lonza and Novartis. The analysis covers various segments, production technologies, and applications, offering a detailed outlook on the industry's trajectory through 2032.
Pfizer's shares have shown mixed performance recently, with a slight decline to EUR 24.50 on February 13, 2025, following a positive trading day that saw a rise to EUR 25.22. The company reported a 7% increase in annual revenue to $63.6 billion for 2024, driven by strong sales of Covid-19 drugs and other key products, while maintaining a shareholder-friendly dividend policy. Analysts have adjusted their price targets, with ratings ranging from "Buy" to "Neutral," reflecting a cautious but optimistic outlook for 2025.
Pfizer is navigating challenges, including a reinstated lawsuit affecting its diversity fellowship program, which has pressured its share price. As of January 9, 2025, shares closed at EUR 26.03, reflecting a slight decline, while UBS and JPMorgan maintain a "Neutral" rating with price targets of USD 29 and USD 30, respectively. Despite uncertainties, Pfizer reported strong fourth-quarter results, exceeding expectations with revenues of $17.76 billion, and is targeting sales of $61 to $64 billion for 2025.
Verdiva Bio has launched with a $410 million series A to develop weight loss drugs, including a weekly oral GLP-1 agonist. Roche's Chugai has partnered with Araris Biotech for a deal potentially worth over $780 million to create multi-payload antibody-drug conjugates. Meanwhile, Astellas has halted its early-stage lymphoma CAR-T therapy following a pipeline review, and Merck has acquired a vaccine plant in Ireland from WuXi Biologics for €500 million.
The global cancer immunotherapy market is projected to reach $135.2 billion in 2024, growing at a CAGR of 9.8% to $236.9 billion by 2030, driven by rising cancer prevalence and demand for effective treatments. North America leads the market, while Asia-Pacific is the fastest-growing region. Monoclonal antibodies dominate the product segment, with lung cancer applications holding the largest market share, and breast cancer expected to grow the fastest.
The Congestive Heart Failure market is poised for significant growth, driven by an increase in prevalence and the introduction of innovative therapies like finerenone, tirzepatide, and semaglutide. Key players such as Novartis, Eli Lilly, and Bayer are advancing their drug candidates through clinical development, while off-label therapies and generics continue to dominate the current market landscape. The FDA's recent approvals and label expansions are expected to further enhance treatment options and accessibility for patients.
CRISPR Therapeutics has proposed the election of Briggs Morrison, M.D., to its Board of Directors at the upcoming annual general meeting. With over 30 years in the pharmaceutical industry, Morrison brings extensive experience in clinical development, having overseen the approval of several notable drugs. He expressed enthusiasm for joining the innovative company and contributing to its mission of developing transformative gene-based medicines.
Merck & Co., Inc.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
goldman sachs group reports strong earnings but analysts suggest better investment options
12:40 31.03.2025
goldman sachs reports strong quarterly earnings and dividend announcement
Merck & Co., Inc.
Morgan Stanley
Wells Fargo & Company
UBS Group AG
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Citigroup Inc.
USA
Show more
12:06 30.03.2025
Goldman Sachs raises AstraZeneca target amid promising drug development and expansion
08:50 28.03.2025
high potency active pharmaceutical ingredients market trends and future growth prospects
Merck & Co., Inc.
Roche Diagnostics AG
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd
BASF AG
Novartis International AG
Lonza Group AG
Bristol-Myers Squibb Co
Cambrex Corporation
Seqens
Pfizer Inc.
Sanofi Aventis SA
Bayer AG
CARBOGEN AMCIS AG
Alice Mutum
Viju Shah
Show more
10:02 26.03.2025
Pfizer reports strong fourth quarter results and maintains positive 2025 outlook
14:10 13.02.2025
Pfizer faces challenges as share price shows mixed performance in 2025
United States Dollar
Euro
Merck & Co., Inc.
Pfizer Inc.
USA
CHE
Albert Bourla
Chris Schott
Raphael Schicho
Akash Tewari
Show more
16:00 04.02.2025
pharmaceutical industry updates on mergers recalls and new drug developments
Euro
United States Dollar
Hoffmann-La Roche AG
Johnson & Johnson
Merck & Co., Inc.
Moderna, Inc.
CHE
CHN
IRL
Stéphane Bancel
Joe Biden
Show more
15:00 10.01.2025
global cancer immunotherapy market projected to reach 236.9 billion by 2030
United States Dollar
GSK plc
Bristol-Myers Squibb Company
Bayer AG
Eli Lilly and Company
Pfizer Inc.
Merck & Co., Inc.
Novartis AG
Immunocore Holdings plc
AstraZeneca PLC
Amgen Inc.
F. Hoffmann-La Roche Ltd.
IND
FRA
ARG
CAN
ESP
USA
BRA
CHN
MEX
DEU
ITA
JPN
GBR
KOR
Show more
10:06 10.01.2025
congestive heart failure market poised for significant growth by 2034
United States Dollar
Mesoblast Ltd
Eli Lilly and Co
Boehringer Ingelheim KG
Bayer AG
Merck & Co., Inc.
Bristol-Myers Squibb Co
Intra-Cellular Therapies, Inc.
BioCardia, Inc.
Novo Nordisk A/S
scPharmaceuticals Inc.
Lexicon Pharmaceuticals, Inc.
Cytokinetics, Incorporated
Novartis AG
Tenax Therapeutics, Inc.
AstraZeneca PLC
Amgen Inc.
Otsuka Pharmaceutical Co. Ltd.
FRA
DEU
ITA
JPN
GBR
USA
Show more
15:50 07.01.2025
crispr therapeutics proposes briggs morrison for board of directors
United States Dollar
Pfizer Inc.
AstraZeneca PLC
CRISPR Therapeutics AG
Merck & Co., Inc.
USA
Briggs Morrison
Samarth Kulkarni
Show more
14:04 07.01.2025
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Industry Mergers & Acquisitions
Finance Mergers & Acquisitions
Global Financial Events
Banking Regulations
Workplace Trends
Retail and Consumer Goods
CEO Changes
Domestic Politics
Market Analysis and Predictions
Government Policies
Global Trade Developments
Central Bank Actions
Startups & Entrepreneurship
Elections & Campaigns
Hedge Funds & Private Equity
Supply Chain Management
Financial Scams and Security
Countries:
Companies:
Tesla, Inc.
JPMorgan Chase & Co.
Barclays PLC
Deutsche Bank Money Market PP
UniCredit S.p.A.
Banco BPM S.p.A.
Credit Suisse Lux Digital Healt
Bank of America Corporation
Apple Inc.
BNP Paribas SA
UBS Group AG
The Goldman Sachs Group, Inc.
Banco Santander, S.A.
Commerzbank AG
Credit Suisse Strategic Income I
CREDIT AGRICOLE
SpaceXCoin USD
Lloyds Banking Group plc
Wells Fargo & Company
Amazon.com, Inc.
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Chinese Yuan
Indian Rupee
Japanese Yen
South Korean Won
Danish Krone
Hong Kong Dollar
Australian Dollar
Offshore Chinese Yuan
Canadian Dollar
Mexican Peso
Singapore Dollar
Norwegian Krone
Filipino Peso
Indonesian Rupiah
Russian Ruble
Chilean Peso
People: